SGLT2 Inhibition: A New Glimmer of Hope to Slow Chronic Kidney Disease Progression in Children?
Klinische Pädiatrie · 01.07.2026 · 238 (04) · 230-231
DOI: 10.1055/a-2431-6764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.07.2026. Verfasst von Emre Leventoğlu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Nephrology, Konya City Hospital, Konya, Turkey.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Sodium-glucose cotransporter 2 (SGLT2) is a transporter protein expressed in the proximal tubule and is responsible for the reabsorption of approximately 90% of filtered glucose with sodium (Reig T et al. Am J Physiol Renal Physiol 2014;306:F188–193). SGLT2 inhibitors (SGLT2i) were developed to control plasma glucose in patients with type 2 diabetes mellitus. During their use, they have been shown to reduce the risk of myocardial infarction, heart failure and cardiovascular mortality and slow the progression of kidney diseases (Palmer BF et al. Clin J Am Soc Nephrol 2023; 18: 279–289). Empagliflozin, an SGLT2i, reduces the risk of nephropathy in patients with type 2 diabetes mellitus. Compared with placebo, it reduces the risk of serum creatinine doubling by 44% and the risk of developing kidney failure by 55% (Wanner C et al. N Engl J Med 2016; 375: 323–334). In a more recent double-blind, placebo-controlled meta-analysis of adults using SGLT2i for at least 6 months, SGLT2i reduced the risk of progression of kidney disease, defined as a 50% reduction in estimated glomerular filtration rate (eGFR), by 37% compared with placebo (relative risk 0.63, 95% confidence interval 0.58–0.69), with similar results in patients with and without diabetes (SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Lancet 2022;400:1788-1801). In a randomized controlled trial of patients with chronic kidney disease with an eGFR of 20-45 ml/min/1.73 m 2 or an eGFR of 45-90 ml/min/1.73 m 2 with albuminuria, progression of kidney disease or death from cardiovascular causes occurred less frequently in the empagliflozin group than in placebo during a median follow-up of 2 years (hazard ratio 0.72, 95% confidence interval 0.64–0.82). In additon, this trial found no evidence that the effect size varied significantly according to primary kidney disease (The EMPA-KIDNEY Collaborative Group. N Engl J Med 2023; 388: 117–127). Publication History Article published online: 28 October 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Autor:innen und Institutionen
- Pediatric Nephrology, Konya City Hospital, Konya, Turkey.
- Pediatric Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.
ORCID-Profile: Emre Leventoğlu
Zitieren
APA
Leventoğlu, E., & Bakkaloğlu, S. A. (2026). SGLT2 Inhibition: A New Glimmer of Hope to Slow Chronic Kidney Disease Progression in Children?. Klinische Pädiatrie, 238(04), 230-231. https://doi.org/10.1055/a-2431-6764
Vancouver
Leventoğlu E, Bakkaloğlu SA. SGLT2 Inhibition: A New Glimmer of Hope to Slow Chronic Kidney Disease Progression in Children?. Klinische Pädiatrie. 2026;238(04):230-231. doi:10.1055/a-2431-6764
BibTeX
@article{Leventolu2026,
author = {Leventoğlu, Emre and Bakkaloğlu, Sevcan A},
title = {SGLT2 Inhibition: A New Glimmer of Hope to Slow Chronic Kidney Disease Progression in Children?},
journal = {Klinische Pädiatrie},
year = {2026},
volume = {238},
number = {04},
pages = {230--231},
doi = {10.1055/a-2431-6764}
}
EUVIMED